Sources confirm that a protester was shot this morning outside a US-funded Ebola treatment centre in Kisumu, western Kenya. The victim, a 24-year-old local journalist, is in critical condition. Witnesses say security guards opened fire as a crowd of 200 demonstrators tried to block a convoy of vehicles carrying medical supplies. The protesters accuse the centre of conducting illegal vaccine trials.
British diplomats in Nairobi have issued an urgent call for restraint. 'We are deeply concerned by the escalation of violence,' said a Foreign Office spokesperson. 'All parties must step back from the brink.' The US Embassy has not commented, but internal cables seen by this reporter reveal that the Centers for Disease Control temporarily suspended operations at the facility.
This is not an isolated incident. The centre, built with a $50 million grant from the US Agency for International Development, has been a flashpoint since it opened last year. Local leaders claim the Americans are testing experimental drugs on vulnerable populations. The company contracted to run the facility, a Delaware-registered firm called Global Health Solutions, has a chequered history. Documents uncovered by this reporter show that one of its directors is a former executive of a pharmaceutical giant fined $3 billion for marketing an antipsychotic drug for unapproved uses.
The shooting threatens to derail delicate negotiations between the Kenyan government and the opposition. The British High Commissioner met privately with President Ruto's chief of staff last night. 'We urge a full and transparent investigation,' the Foreign Office statement added. But activists say the Kenyan police have already arrested six protesters and charged them with terrorism.
As I write this, the sounds of tear gas and chanting drift across the city. The protesters are not backing down. And the men in suits in Washington and London are scrambling to control a narrative that is slipping away. This story is far from over. Follow the money and you'll find the truth. I'm Marcus Stone, and I'm not stopping until I uncover it.
